Depósito Académico >
CIMA (Centro de Investigación Médica Aplicada) >
Área de Terapia génica y Hepatología >
Inmunología terapia génica >
DA - CIMA - Terapia génica y Hepatología - Inmunología terapia génica - Artículos de revista >
|Thrombopenic purpura induced by a monoclonal antibody directed to a 35-kilodalton surface protein (p35) expressed on murine platelets and endothelial cells|
|Authors: ||Rodriguez-Calvillo, M. (Mercedes)|
Gabari, I. (Izaskun)
Duarte, M. (Marina)
Mazzolini, G. (Guillermo)
Rifon, J. (Jose)
Rocha, E. (Eduardo)
Prieto, J. (Jesús)
Melero, I. (Ignacio)
|Keywords: ||Antibodies, Monoclonal/toxicity|
|Issue Date: ||2001|
|Publisher version: ||http://www.sciencedirect.com/science/article/pii/S0301472X01006300|
|Citation: ||Rodriguez-Calvillo M, Gabari I, Duarte M, Mazzolini G, Rifon J, Rocha E, et al. Thrombopenic purpura induced by a monoclonal antibody directed to a 35-kilodalton surface protein (p35) expressed on murine platelets and endothelial cells. Exp Hematol 2001 May;29(5):589-595.|
With the aim of obtaining monoclonal antibodies (mAbs) against mouse endothelial surface antigens, immunization of rats with a mouse-derived endothelial cell line (PY4.1) and subsequent hybridoma production were performed.
MATERIALS AND METHODS:
One of the mAbs produced by hybridoma EOL5F5 was selected for its surface binding to endothelial cell lines, and identification of the mAb-recognized antigen was performed by immunoprecipitation. Experiments were performed to analyze the effects of EOL5F5 on systemic administration to mice.
EOL5F5-recognized antigen was a single band of 35 kDa under reducing and nonreducing conditions, features that do not match other known differentiation antigens with comparable tissue distribution. In vivo administration of purified EOL5F5 mAb to mice (n = 20) induced intense cutaneous purpura as well as severe but transient thrombocytopenia. Expression of EOL5F5-recognized antigen was detected on platelets from which it immunoprecipitated a moiety of identical electrophoretic pattern in SDS-PAGE, as the one recognized on endothelial cells. Immunohistochemically, EOL5F5-recognized antigen (p35) also was expressed on dermal capillaries, suggesting that, in addition to thrombocytopenia, damaging effects of the antibody on endothelial cells also might cause the observed purpura.
Our results show induction of thrombocytopenic purpura in mice with an mAb against a single antigenic determinant expressed on both platelets and endothelium. EOL5F5 mAb injection sets the stage for useful experimental models that resemble immune thrombocytopenic purpura.
|Permanent link: ||http://hdl.handle.net/10171/21790|
|Appears in Collections:||DA - Medicina - Medicina Interna - Artículos de revista|
DA - CIMA - Terapia génica y Hepatología - Inmunología terapia génica - Artículos de revista
|Files in This Item:|
| View / Open |
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.